Following the release of CardioGxOne, the first product to detect 213 genes related to hereditary cardiovascular disease and sudden death, in 2015, Admera Health recently released the second AtheroGxOne, a product that detects 84 genes related to lipid disorders and vascular diseases. The company also plans to launch its first clinical product for cancer liquid biopsy in 2017. Since its inception, Admera Health has emerged in the field of clinical comprehensive pharmacogenomics diagnostics. The company has recently developed a series of testing products in the field of cardiovascular genetics, and finally plans to release liquid biopsy products for tumors. Two cardiovascular disease testing products On March 17, Admera released the second next-generation sequencing panel for a variety of cardiovascular disease-related genetic variation tests. The latest product, AtheroGxOne, is an NGS panel that detects 84 genes that are primarily associated with lipid disorders and vascular disease. The company's first cardiovascular disease testing product, the CardioGxOne, released in 2015, can be used to detect mutations in 213 genes associated with hereditary cardiovascular disease and sudden death. Hu Guanghui, president and CEO of Admera, said that although the company launched the first pharmacogenomic testing product PGxOne in 2014, it did not include cardiovascular genetic testing in the forefront of the company's business plan, but the company leaders saw it. The enormous potential of genetic testing in the cardiovascular field. Hu Guanghui said, "Compared with tumors, we have seen cardiovascular disease not being valued. A Spanish company, Health In Code, seized the opportunity to focus on cardiovascular genetics research for many years and has accumulated research in the field of cardiovascular disease genetics. The largest clinical database. Combining our expertise in technology development with their unique database resources, we started this work." The first result of the cooperation between the two parties is CardioGxOne. Zeil Rosenberg, vice president of medical affairs at Admera, said that it is very easy to develop a genetic cardiomyopathy or arrhythmia test based on a mature scientific research base. Admera is not the only company that targets the clinical arena. For example, AmbryGenetics released 10 genetic test panels for hereditary cardiomyopathy and arrhythmias in January 2015. Hu Guanghui said that Health In Code's database covers more than 100,000 people and nearly 40,000 families and their genetic history information. This data has greatly helped Admera's clinical interpretation of cardiovascular genetic testing results. And this is unmatched by many competitors. After the launch of CardioGxOne, Admera and Health in Code have developed AtheroGxOne, a product that focuses on genetic variants associated with cholesterol and triglycerides in vascular diseases, especially familial hypercholesterolemia. Rosenberg said that the development of two test products is more sensitive than a comprehensive heart genetic test panel because the two tests cover different areas of medical practice, one is lipid and vascular disease, and the other is hereditary cardiomyopathy. Or arrhythmia, and the genetic abnormalities associated with the two are completely different. The current clinical utility of dyslipidemia, such as familial hypercholesterolemia (FH) gene testing, is unclear, but Rosenberg said that the recent introduction of new PCSK9 inhibitors on the market provides us with an opportunity to use genetic testing to identify In FH patients, these patients may use this new treatment instead of traditional high-cholesterol diet control, lifestyle changes, or statin therapy because they have little effect on these traditional treatments. Dried Fruit,Freeze Dried Strawberries,Dehydrated Fruit,Dried Goji Berries Xi'an Gawen Biotechnology Co., Ltd , https://www.seoagolyn.com